Clinical Trials Browser

Lymphoma, B-Cell

NCT07162571 2025-09-09

MSTH-CAR002

Phase 1/2 Not yet recruiting

17 enrolled

Lymphoid

Lymphoma, B-Cell

NCT06961669 2025-05-29

ECAR01

Phase NA Recruiting

18 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06758713 2025-01-06

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

Phase 1 Recruiting

60 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Lymphoma, B-Cell, Hematologic Neoplasms

NCT03244176 2024-07-30

AvR-CHOP

Phase EARLY_PHASE1 Active not recruiting

28 enrolled

Lymphoid

Lymphoma, B-Cell

NCT06478381 2024-06-27

L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma

Phase 1 Recruiting

22 enrolled

Lymphoid

Lymphoma, B-Cell

NCT05385263 2022-05-26

Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

Phase 2 Unknown

20 enrolled

Lymphoid

Lymphoma, B-Cell

NCT05286164 2022-04-15

Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART

Phase 2 Unknown

30 enrolled

Lymphoid

Lymphoma, B-Cell

NCT05164770 2021-12-21

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Phase 3 Unknown

160 enrolled

Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04152577 2019-11-05

R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL

Phase 4 Unknown

200 enrolled

Lymphoid

Lymphoma, B-Cell

NCT03569696 2019-04-23

NivoM

Phase 2 Unknown

50 enrolled

Lymphoid

Lymphoma, B-Cell

NCT03881761 2019-03-21

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Phase 1 Unknown

50 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT03881774 2019-03-21

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Phase 1 Unknown

20 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

NCT03101709 2017-04-05

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Phase 1 Unknown

30 enrolled

Lymphoid

Lymphoma, B-Cell

NCT02996617 2016-12-19

PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia

Phase 4 Unknown

240 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Neutropenia, Lymphoma, B-Cell, Lymphoma, T-Cell

Clinical Trials

Anti CD19 Gene Therapy for B-cell Lymphoma

MSTH-CAR002

ECAR01

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

AvR-CHOP

L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma

Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL

NivoM

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia